10:50 AM EST - Cipher Pharmaceuticals Inc. : Announced it has acquired the exclusive Canadian rights to right to develop, market, distribute and sell TRULANCE® (plecanatide) from Synergy Pharmaceuticals Inc. TRULANCE is a once-daily tablet approved by the U.S. Food and Drug Administration for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. Cipher Pharmaceuticals Inc.
shares T.CPH are trading up $0.16 at $4.20.
